Format

Send to

Choose Destination
Protein Sci. 2009 Sep;18(9):1998-2002. doi: 10.1002/pro.192.

Blind docking of pharmaceutically relevant compounds using RosettaLigand.

Author information

1
Department of Biochemistry, University of Washington, Seattle, Washington 98195-7350, USA.

Abstract

It is difficult to properly validate algorithms that dock a small molecule ligand into its protein receptor using data from the public domain: the predictions are not blind because the correct binding mode is already known, and public test cases may not be representative of compounds of interest such as drug leads. Here, we use private data from a real drug discovery program to carry out a blind evaluation of the RosettaLigand docking methodology and find that its performance is on average comparable with that of the best commercially available current small molecule docking programs. The strength of RosettaLigand is the use of the Rosetta sampling methodology to simultaneously optimize protein sidechain, protein backbone and ligand degrees of freedom; the extensive benchmark test described here identifies shortcomings in other aspects of the protocol and suggests clear routes to improving the method.

PMID:
19554568
PMCID:
PMC2777374
DOI:
10.1002/pro.192
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center